We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · March 14, 2013

Cisplatin-Based IP Chemotherapy Associated With Improved Survival in BRCA1+ Ovarian Cancer

British Journal of Cancer


Additional Info

British Journal of Cancer
BRCA1 Expression and Improved Survival in Ovarian Cancer Patients Treated With Intraperitoneal Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study
Br. J. Cancer 2013 Mar 05;[EPub Ahead of Print], JL Lesnock, KM Darcy, C Tian, et al

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading